Citations 2
Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia
Ailawadhi, Sikander, Challagulla, Swetha, Chuang, Po-Ya, Furnback, Wesley , Yang, Keri, Ailawadhi, Sikander , Chuang, Po-Ya , Yang, Keri
Expert Review of Hematology | February 10, 2026 | Volume: 19 | Issue: 5 | Pages: 539-546
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia
Shadman, Mazyar, Chanan‐Khan, Asher , Campbell, David , Xue, Mei, Massoudi, Marjan , Williams, Rhys, Yang, Keri, Tam, Constantine S., Tam, Constantine S. , Shadman, Mazyar , Shadman, Mazyar , Xue, Mei , Tam, Constantine S , Williams, Rhys
Future Oncology | January 31, 2026 | Volume: 22 | Issue: 3 | Pages: 339-348